|
Clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions incorporated the 21-gene recurrence score (RS): Elderly (≥70 yrs) vs younger patients (Pts). |
|
|
Consulting or Advisory Role - Novartis |
Research Funding - Lilly (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Teva (Inst) |
Travel, Accommodations, Expenses - Genomic Health |
|
|
No Relationships to Disclose |
|
|
Research Funding - Lilly (Inst) |
|
|
Honoraria - AstraZeneca; Novartis; Oncotest-Teva; Oncotest-Teva; Pfizer; Rafa Pharmaceutical; Rafa Pharmaceutical; Roche |
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche |
Speakers' Bureau - Genomic Health; Pfizer; Roche |
Research Funding - Lilly; Novartis; Roche; Tesaro; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche |
|
|
|
|
|
Consulting or Advisory Role - Bayer; Caris Life Sciences; Genomic Health; Oncotest-Teva; Roche |
|
|
Travel, Accommodations, Expenses - Medison; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Genomic Health |
Stock and Other Ownership Interests - Genomic Health |
Patents, Royalties, Other Intellectual Property - Genomic Health |
|
|
Employment - Genomic Health |
Stock and Other Ownership Interests - Genomic Health |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis; Pfizer |
Travel, Accommodations, Expenses - Medison; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche |
Speakers' Bureau - AstraZeneca; Pfizer; Roche |
Travel, Accommodations, Expenses - BMS Brazil; Roche |
|
|
Employment - Genomic Health |
Leadership - Genomic Health |
Stock and Other Ownership Interests - Genomic Health |
Patents, Royalties, Other Intellectual Property - Genomic Health |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |